AM-Pharma BV of the Netherlands has raised €12.2 million for the further clinical development of its recombinant human alkaline phosphatase product for acute kidney injury and ulcerative colitis – its second major fundraising in three years
AM-Pharma BV of the Netherlands has raised €12.2 million for the further clinical development of its recombinant human alkaline phosphatase product for acute kidney injury and ulcerative colitis – its second major fundraising in three years